These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8862715)

  • 21. Development of a 5-fluorouracil-loaded PLGA microsphere delivery system by a solid-in-oil-in-hydrophilic oil (S/O/hO) novel method for the treatment of tumors.
    Lin Q; Cai Y; Yuan M; Ma L; Qiu M; Su J
    Oncol Rep; 2014 Dec; 32(6):2405-10. PubMed ID: 25231485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kidney- and site-selective delivery of 5-fluorouracil utilizing the absorption on the kidney surface in rats.
    Kawakami S; Horimoto T; Nishida K; Hirayama R; Mukai T; Nakashima M; Sasaki H; Sakaeda T; Nakamura J
    Biol Pharm Bull; 2002 Jul; 25(7):928-30. PubMed ID: 12132672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of magnetic nanoparticles coated by 5-fluorouracil imprinted polymer for controlled drug delivery in mouse breast cancer model.
    Hashemi-Moghaddam H; Kazemi-Bagsangani S; Jamili M; Zavareh S
    Int J Pharm; 2016 Jan; 497(1-2):228-38. PubMed ID: 26621688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms.
    Akbulut H; Tang Y; Maynard J; Zhang L; Pizzorno G; Deisseroth A
    Clin Cancer Res; 2004 Nov; 10(22):7738-46. PubMed ID: 15570008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
    Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preparation and evaluation of chitosan based thermoreversible gels for intraperitoneal delivery of 5-fluorouracil (5-FU).
    Depani BP; Naik AA; Nair HA
    Acta Pharm; 2013 Dec; 63(4):479-91. PubMed ID: 24451073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites.
    Wang GP; Guan YS; Jin XR; Jiang SS; Lu ZJ; Wu Y; Li Y; Li M; Luo F
    J Gastroenterol Hepatol; 2010 May; 25(5):985-90. PubMed ID: 20546454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of intrapericardial administration of 5-fluorouracil.
    Lerner-Tung MB; Chang AY; Ong LS; Kreiser D
    Cancer Chemother Pharmacol; 1997; 40(4):318-20. PubMed ID: 9225949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical delivery of 5-fluorouracil (5-FU) by 1,3-bisalkylcarbonyl-5-FU prodrugs.
    Beall HD; Sloan KB
    Int J Pharm; 2002 Jan; 231(1):43-9. PubMed ID: 11719012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.
    Garcia RAG; Saydoff JA; Bamat MK; von Borstel RW
    Toxicol Appl Pharmacol; 2018 Aug; 353():67-73. PubMed ID: 29908244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and evaluation of novel microemulsion based oral formulations of 5-fluorouracil using non-everted rat intestine sac model.
    Shishu ; Kamalpreet ; Maheshwari M
    Drug Dev Ind Pharm; 2012 Mar; 38(3):294-300. PubMed ID: 21864111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
    Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
    J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
    Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
    Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
    Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
    Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation and characterization of 5-fluorouracil-loaded PLLA-PEG/PEG nanoparticles by a novel supercritical CO2 technique.
    Zhang C; Li G; Wang Y; Cui F; Zhang J; Huang Q
    Int J Pharm; 2012 Oct; 436(1-2):272-81. PubMed ID: 22721846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formulation and pharmacokinetics of thermosensitive stealth® liposomes encapsulating 5-Fluorouracil.
    Al Sabbagh C; Tsapis N; Novell A; Calleja-Gonzalez P; Escoffre JM; Bouakaz A; Chacun H; Denis S; Vergnaud J; Gueutin C; Fattal E
    Pharm Res; 2015 May; 32(5):1585-603. PubMed ID: 25416027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of carbogen breathing on the pharmacodynamics of 5-fluorouracil in a murine colon carcinoma.
    Kamm YJ; Heerschap A; Wagener DJ
    Eur J Cancer; 2000 Jun; 36(9):1180-6. PubMed ID: 10854952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of fluorouracil antitumor activity by folic acid in a murine model system.
    Raghunathan K; Priest DG
    Biochem Pharmacol; 1999 Sep; 58(5):835-9. PubMed ID: 10449194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.